In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol

European Journal of Clinical Pharmacology

Volumn 55, Issue 8, 1999, Pages 599-604

  Pan, L ^a   Belpaire, F M ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Cytochrome P450; Haloperidol; Human liver microsomes

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; FURAFYLLINE; HALOPERIDOL; KETOCONAZOLE; MONOCLONAL ANTIBODY; PHENACETIN O DEETHYLASE; QUINIDINE; RECOMBINANT PROTEIN; REDUCED HALOPERIDOL;

ADULT; ANIMAL CELL; ARTICLE; BACULOVIRUS; CHILD; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INSECT; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

BIOTRANSFORMATION; CHILD; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE ANTAGONISTS; ENZYME INHIBITORS; HALOPERIDOL; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; THEOPHYLLINE;

EID: 0032860134     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050679     Document Type: Article

References (25)

1. Usuki E, Van Der Schyf CJ, Castagnoli N (1998) Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP. Drag Metab Rev 30: 809-826
2. Pan LP, Wijnant P, De Vriendt C, Rosseel MT, Belpaire FM (1997) Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 44: 557-564
3. Pan LP, De Vriendt C, Belpaire FM (1998) In vitro characterisation of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 8: 383-389
4. Fang J, Baker GB, Silverstone PR Coutts RT (1997) Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 17: 227-233
5. Kudo S, Odomi M (1998) Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur J Clin Pharmacol 54: 253-259
6. Avent KM, Gillam EMJ (1998) Cytochrome P450-mediated bioactivation of haloperidol to toxic pyridinium metabolites (abstract 89). Proceedings of the 12th International Symposium on Microsomes and drug oxidations. Montpellier
7. Eyles DW, McGrath JJ, Pond SM (1996) Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology (Berl) 125: 214-219
8. Inaba T, Jurima M, Mahon WA, Kalow W (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 13: 443-448
9. Tyndale RF, Kalow W, Inaba T (1991) Oxidation of reduced haloperidol to haloperidol: involvement human P450 IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 31: 655-660
10. Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, Zarifian E (1989) Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 27: 272-275
11. LLerena A, Alm C, Dahl M, Ekqvist B, Bertilsson L (1992) Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype. Ther Drug Monit 14: 92-97
12. LLerena A, Dahl M, Ekqvist B, Bertilsson L (1992) Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 14: 261-264
13. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egan M, Elkashef A, Liboff S, Linnoila M (1994) Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 14: 340-343
14. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P (1995) Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 31: 347-353
15. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 72: 248-252
16. Pan L, Rosseel MT, Belpaire FM (1998) Comparison of two high-performance liquid Chromatographic methods for monitoring plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit 20: 224-230
17. Newton DJ, Wang RW, Lu AYH (1995) Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23: 154-158
18. Young D, Midha KK, Fossler MJ, Hawes EM, Hubbard JW, McKay G, Korchinski ED (1993) Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in human: implications for the involvement of cytochrome P450 IID6. Eur J Clin Pharmacol 44: 433-438
19. Silas JH, McGourty JC, Lennard MS, Tucker GT, Woods HF (1985) Polymorphic metabolism of metoprolol: clinical studies. Eur J Clin Pharmacol 28: 85-88
20. Dahl-Puustinen ML, Liden A, Alm C, Nordin C, Bertilsson L (1989) Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 46: 78-81
21. Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y, Hayashi K (1997) Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 7: 415-418
22. Lane H, Hu O YP, Jann MW, Deng HC, Lin HN, Chang WH (1997) Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Res 69: 105-111
23. Caccia S (1998) Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34: 281-302
24. Lin JH, Lu AYH (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35: 361-390
25. ZumBrunnen TL, Jann MW (1998) Drug interactions with antipsychotic agents. CNS Drugs 9: 381-401